Vitiligo in a patient during Chemotherapy with Dasatinib

抄録

　Dasatinib is a divond-generation multi-target tyrosine kinase inhibitor (TKI) that has activity against many imatinib-resistant BCR-ABL mutant forms, c-Kit tyrosine kinases, and Src. While skin hypopigmentation is a well-recognized adverse effect of first generation TKIs; it has rarely been reported with dasatinib yet. We report a rare case of vitiligo induced by dasatinib. A 41-year-old male with a history of chronic myeloid leukemia was initiated on dasatinib as part of a treatment. After 2 months of treatment, he developed skin hypopigmentation on left shoulder and arm area. With skin biopsy, the histopathologic diagnosis with HMB45 and Melan-A staining was confirmed by vitiligo. The patient with dasatinib-induced vitiligo continued to receive treatment with the drug during which time areas of skin hypopigmentation persisted and progressed. We reported rare case of vitiligo induced by treatment of dasatinib.